Related Experiment Videos
[Remantadine in the treatment of influenza in children]
Insights
Remantadine effectively treated influenza A and B infections in children aged 3-14. Early treatment reduced fever, complications, and illness duration without impacting immunity.
Area of Science:
- Pediatrics
- Virology
- Pharmacology
Background:
- Influenza remains a significant respiratory illness in children.
- Antiviral therapies are crucial for managing influenza symptoms and complications.
Purpose of the Study:
- To evaluate the therapeutic efficacy of remantadine in pediatric influenza patients.
- To assess the safety and impact of remantadine on immune responses.
Main Methods:
- A study involving in- and out-patients aged 3-14 years during influenza epidemics.
- Remantadine administered at 1.5 mg/kg, three times daily for three days, starting on day 1 or 2 of illness.
- Assessment of clinical outcomes, including fever, intoxication symptoms, complications, and disease duration.
Main Results:
- Remantadine demonstrated curative effects in influenza A, B, and mixed infections.
- Treatment reduced fever, complications, and duration of intoxication and overall illness.
- Earlier administration (day 1) showed more pronounced efficacy.
- No toxic effects on basic bodily functions or immune responses (cellular, humoral, antibody) were observed.
Conclusions:
- Remantadine is an effective and safe therapeutic agent for pediatric influenza.
- Early intervention with remantadine can significantly improve clinical outcomes in children.
- The drug's efficacy may be linked to its antitoxic activity, with no adverse effects on the pediatric immune system.
Abstract:
The therapeutical efficacy of remantadine was studied in influenza in- and out-patients aged 3-14 years during consecutive influenza epidemics. The drug was given to ill children on the first or second day from the onset of the disease at a dose of 1.5 mg/kg of body weight 3 times a day for 3 days. The curative effect of remantadine was established not only in influenza A, but also in influenza B infections, as well as in mixed infections with other respiratory agents and with pathogens of non-influenza etiology, which might be the result of its antitoxic activity. Remantadine application decreased fever and complication rates and reduced the duration of intoxication symptoms and the diseases as a whole. A more pronounced drug activity was observed when given to children on the first day of the diseases. Remantadine exerted no toxic effect on the basic functions of the child's body. Ill children displayed no inhibitory activity on cell and humoral immunity, as well as on a serum antibody response to hemagglutinin of influenza virus.